These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36678540)

  • 1. Design, Synthesis, Biological Evaluation, and Molecular Dynamics Studies of Novel Lapatinib Derivatives.
    Elkamhawy A; Son S; Lee HY; El-Maghrabey MH; Hamd MAE; Alshammari SO; Abdelhameed AA; Alshammari QA; Abdeen A; Ibrahim SF; Mahdi WA; Alshehri S; Alnajjar R; Choi WJ; Al-Karmalawy AA; Lee K
    Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.
    Elkamhawy A; Farag AK; Viswanath AN; Bedair TM; Leem DG; Lee KT; Pae AN; Roh EJ
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5147-54. PubMed ID: 26475520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
    Li DD; Qin YJ; Sun J; Li JR; Fang F; Du QR; Qian Y; Gong HB; Zhu HL
    PLoS One; 2013; 8(8):e69427. PubMed ID: 23936329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines.
    Son S; Elkamhawy A; Gul AR; Al-Karmalawy AA; Alnajjar R; Abdeen A; Ibrahim SF; Alshammari SO; Alshammari QA; Choi WJ; Park TJ; Lee K
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2202358. PubMed ID: 37096560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors.
    Farouk AKBAW; Abdelrasheed Allam H; Rashwan E; George RF; Abbas SE
    Bioorg Chem; 2022 Nov; 128():106099. PubMed ID: 35994884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of novel quinazoline derivatives with high selectivity for HER2 over EGFR.
    Lee JW; Choi C; Kim J; Lee S; Kim J; Lee Y; Min KH
    Arch Pharm Res; 2022 Mar; 45(3):123-141. PubMed ID: 35314953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinazolin-4(3
    Mirgany TO; Abdalla AN; Arifuzzaman M; Motiur Rahman AFM; Al-Salem HS
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2055-2067. PubMed ID: 34551654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L
    Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2.
    Bello M; Guadarrama-García C; Rodriguez-Fonseca RA
    J Comput Aided Mol Des; 2020 Mar; 34(3):293-303. PubMed ID: 31828486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold.
    Yin S; Tang C; Wang B; Zhang Y; Zhou L; Xue L; Zhang C
    Eur J Med Chem; 2016 Sep; 120():26-36. PubMed ID: 27187856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
    Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
    Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
    Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
    Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and energetic basis for the molecular recognition of dual synthetic vs. natural inhibitors of EGFR/HER2.
    Bello M; Saldaña-Rivero L; Correa-Basurto J; García B; Sánchez-Espinosa VA
    Int J Biol Macromol; 2018 May; 111():569-586. PubMed ID: 29329808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
    Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and evaluation of cytisine N-isoflavones as novel EGFR/HER2 dual inhibitors.
    Wang Y; Yin X; Chen L; Yin Z; Zuo Z
    Bioorg Chem; 2022 Oct; 127():105868. PubMed ID: 35816874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.
    Mowafy S; Galanis A; Doctor ZM; Paranal RM; Lasheen DS; Farag NA; Jänne PA; Abouzid KA
    Bioorg Med Chem; 2016 Aug; 24(16):3501-12. PubMed ID: 27288180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model.
    Nakayama A; Takagi S; Yusa T; Yaguchi M; Hayashi A; Tamura T; Kawakita Y; Ishikawa T; Ohta Y
    J Cancer; 2013; 4(7):557-65. PubMed ID: 23983820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.
    Ju Y; Wu J; Yuan X; Zhao L; Zhang G; Li C; Qiao R
    J Med Chem; 2018 Dec; 61(24):11372-11383. PubMed ID: 30508379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
    Hossam M; Lasheen DS; Ismail NSM; Esmat A; Mansour AM; Singab ANB; Abouzid KAM
    Eur J Med Chem; 2018 Jan; 144():330-348. PubMed ID: 29275232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.